Recombinant human erythropoietin reduces free erythrocyte protoporphyrin levels in patients on chronic dialysis

V. Piazza, G. Villa, F. Galli, S. Segagni, G. Bovio, F. Poggio, L. Picardi, A. Salvadeo

Research output: Contribution to journalArticlepeer-review

Abstract

We studied the significance of free erythrocyte protoporphyrin (FEP) in relation to iron status, aluminium levels and anemia in uremic patients on chronic dialysis. All but 1 patient showed high FEP values closely related to the degree of anemia. Increased FEP levels are due to a defective heme synthesis, not related to iron deficiency or aluminium overload. Treatment of anemia with recombinant human erythropoietin reduced FEP values. We therefore hypothesize that recombinant human erythropoietin ameliorates an enzymatic defect in heme synthesis.

Original languageEnglish
Pages (from-to)54-57
Number of pages4
JournalNephron
Volume61
Issue number1
Publication statusPublished - 1992

Keywords

  • Erythropoietin
  • Heme
  • Hemodialysis
  • Porphyrins

ASJC Scopus subject areas

  • Nephrology

Fingerprint Dive into the research topics of 'Recombinant human erythropoietin reduces free erythrocyte protoporphyrin levels in patients on chronic dialysis'. Together they form a unique fingerprint.

Cite this